Insight
Biosimilars are not new drugs, but rather they are copies of biological drugs that have been used to treat many diseases and conditions. They are highly similar to originator biological agents but are less expensive. Biosimilars are expected to deliver huge savings to healthcare systems and increase access to treatment in the coming years as expensive biological drugs lose patent protection.
Biosimilars are available today and they could change the treatment of many serious diseases such as cancer, inflammatory bowel diseases, or rheumatoid and psoriatic arthritis.
Despite the obvious qualitative leap that they represent for the treatment of these...